Cannabis and Psychosis

Speaker Brian Miller. Substance use comorbidity in psychotic disorders has been described as “the rule rather than the exception”, and is often deleterious to the clinical course of illness. Cannabis (marijuana) is one of the most commonly used substances by patients with schizophrenia and related psychotic disorders. Modulation of the endocannabinoid system by the main psychoactive component in marijuana, Δ9-tetrahydrocannabinol, can induce acute psychosis and cognitive impairment. Over the past two decades, there has been extensive research on the association between cannabis and psychosis. The purpose of this presentation is to synthesize recent research in this area, including associations between cannabis and psychosis risk; the epidemiology and phenomenology of psychosis and comorbid cannabis use; and associations between cannabis use and clinical course, and outcomes in psychosis.

Video link: https://vimeo.com/649669247/39a18f94a6

Speaker Details

Full Name
Brian Miller

Position
MD, PhD, MPH

Bio
Dr. Miller currently focuses on clinical schizophrenia research, including inflammation/immune dysfunction, cardiometabolic abnormalities, and insomnia. He is currently funded by the NIMH and Stanley Medical Research Foundation and has over 100 peer-reviewed publications. Dr. Miller has been recognized with several awards, including a 2011 Exemplary Psychiatrist Award from the National Alliance on Mental Illness, the 2015 Augusta University Outstanding Young Clinical Science Faculty Award, and the 2017 OSU College of Medicine Early Career Achievement Alumni Award. He is an editorial board member of Schizophrenia Bulletin, BMC Psychiatry, and Psychiatric Times. In addition to his research, Dr. Miller provides clinical care for patients with schizophrenia and supervises and teaches residents and medical students in general psychiatry.